Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + ICE in Relapsed/Refractory Classic Hodgkin's Lymphoma
NCT04044222Phase 3Unknown
- Sponsor
- Innovent Biologics
- Start
- Oct 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in classic Hodgkin lymphoma (cHL), sponsored by Innovent Biologics. Status: unknown.
02
Drugs
sintilimab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04044222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044222.